Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 19/20 | 0.55 |
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.55 |
| ▸ | PIM3 | Q86V86 | 9/20 | 0.55 |
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9881936 | 0.84 | PRKCA (0.64) | PIM1PIM2PIM3PRKCAPRKCQ | |
| SCHEMBL16256476 | 0.84 | PRKCQ (0.58) | PIM1PIM2PIM3PRKCQPRKCD | |
| SCHEMBL9881926 | 0.80 | PIM1 (0.65) | PIM1PIM2PIM3PRKCAPRKCQ | |
| SCHEMBL9882138 | 0.78 | PIM1 (0.52) | PIM1PIM2PIM3PRKCAPRKCQ | |
| SCHEMBL14725582 | 0.76 | PRKCQ (0.53) | PIM1PRKCAPRKCQPRKCD | |
| SCHEMBL9881986 | 0.75 | PIM1 (0.61) | PIM1PIM2PIM3 | |
| SCHEMBL14713855 | 0.73 | PIM1 (0.74) | PIM1PIM2PIM3 | |
| SCHEMBL2357126 | 0.73 | JAK2 (0.40) | PIM1 | |
| SCHEMBL14688717 | 0.72 | PIM1 (1.00) | PIM1PIM2PIM3 | |
| SCHEMBL14689216 | 0.71 | PIM1 (1.00) | PIM1PIM2PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895740-B2 | Pyrazolopyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895740-B2 | Pyrazolopyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895740-B2 | Pyrazolopyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130053388-A1 | PYRAZOLOPYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053388-A1 | PYRAZOLOPYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053388-A1 | PYRAZOLOPYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2011094288-A1 | PYRAZOLOPYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053388-A1 | PYRAZOLOPYRAZINE KINASE INHIBITORS | MAP3K5, MAP3K2, MAP3K20 | PIM1 275/4885PIM2 208/4885PIM3 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.